[
  {
    "ts": null,
    "headline": "Moderna, Merck Report Positive Results From Cancer-Vaccine Study",
    "summary": "Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.",
    "url": "https://finnhub.io/api/news?id=1513dc35651e967fc1735d59c48d413568b70e6df6c6611ae8118c5380258707",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768910280,
      "headline": "Moderna, Merck Report Positive Results From Cancer-Vaccine Study",
      "id": 138186680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.",
      "url": "https://finnhub.io/api/news?id=1513dc35651e967fc1735d59c48d413568b70e6df6c6611ae8118c5380258707"
    }
  },
  {
    "ts": null,
    "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
    "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
    "url": "https://finnhub.io/api/news?id=bc451509fa838b9994d3707b3cc1d826b4277dcf21798801071dc9498daa3177",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768906800,
      "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
      "id": 138185701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
      "url": "https://finnhub.io/api/news?id=bc451509fa838b9994d3707b3cc1d826b4277dcf21798801071dc9498daa3177"
    }
  }
]